US The Bureau of Prisons Just Bought a Ton of Hydroxychloroquine, Trump's COVID-19 Miracle Drug

22:50  07 april  2020
22:50  07 april  2020 Source:   thedailybeast.com

World leaders' posts deleted over false virus info

  World leaders' posts deleted over false virus info Social networks usually leave world leaders’ posts alone - but the pandemic is changing that.Facebook deleted a video from Brazilian President Jair Bolsonaro that claimed hydroxychloroquine was totally effective in treating the virus.

A debate may be raging inside the White House about the efficacy of an anti-malaria drug to treat the novel coronavirus, but the Trump administration isn’t waiting for a resolution. Two federal agencies have already placed purchase orders for the drug.

John Phillips/Getty © Provided by The Daily Beast John Phillips/Getty

The Department of Veterans Affairs and the Justice Department’s Bureau of Prisons have both reported purchases of hydroxychloroquine since March 26, according to federal procurement records.

Bing COVID-19 tracker: Latest numbers by country and state

FDA says anti-malaria drugs touted by Trump for coronavirus care in shortage

  FDA says anti-malaria drugs touted by Trump for coronavirus care in shortage Two anti-malaria drugs touted by President Trump as a potential way to treat the novel coronavirus are now in shortage, the Food and Drug Administration (FDA) said Wednesday.Hydroxychloroquine and chloroquine were both added to the agency's drug shortages list on Tuesday "due to a significant surge in demand."All manufacturers are ramping up production, FDA said, and it is working with them "to ensure this can happen expeditiously and safely."Hydroxychloroquine and chloroquine were both added to the agency's drug shortages list on Tuesday "due to a significant surge in demand.

News to stay informed. Advice to stay safe.
Click here for complete coronavirus coverage from Microsoft News

The Department of Veterans Affairs purchased $40,000 in hydroxychloroquine sulfate tablets from the pharmaceutical company McKesson, and another $168,000 from the Colorado-based generic drug distributor Golden State Medical Supply. Procurement records for both list them as “emergency” purchase orders to deal with the coronavirus outbreak.

The Bureau of Prisons’ purchase order does not mention the coronavirus. But the $60,000 purchase of hydroxychloroquine sulfate tablets from the company Premium Rx National came on March 31—in the midst of a worsening outbreak at the federal correctional facilities that the bureau oversees and days before President Trump announced that he was stockpiling millions of pills of the drug. It appears to be the first time that the BOP has purchased the drug.

India Bans All Exports of Trump’s ‘Game Changer’ Virus Drug

  India Bans All Exports of Trump’s ‘Game Changer’ Virus Drug India put a total ban on exports of hydroxychloroquine, a malaria drug that U.S. President Donald Trump has touted as a “game changer” in the fight against Covid-19. Exports of the drug and its formulations have been prohibited “without any exceptions” and with immediate effect, India’s Directorate General of Foreign Trade said in an April 4 order on its website. The trade regulator had last month restricted overseas shipments of the drug, allowing only limited exceptions such as on humanitarian grounds and for meeting prior commitments.

Neither the VA nor BOP responded to requests for additional information about the purchases, and how, or whether, they would be used in the near-term to treat coronavirus patients.

Gallery by photo services

The use of taxpayer money on hydroxychloroquine by the two agencies came in spite of a heated debate among policymakers and medical professionals about the drug’s effectiveness in treating the virus, and the possibility that a sudden surge in demand for the drug could diminish the supply for those who use it to treat other ailments such as malaria, lupus, and rheumatoid arthritis.

That dispute erupted at a closed-door meeting at the White House on Saturday, as first reported by Axios. At that meeting, White House economic adviser Peter Navarro reportedly clashed with  National Institute of Infectious Diseases director Dr. Anthony Fauci over the efficacy of hydroxychloroquine as a coronavirus treatment.

Trump, for his part, has consistently promoted the drug as a potential panacea in efforts to control the virus. Despite only anecdotal evidence that it has any impact, his supporters have cast dissenting voices as timid at best and hostile at worst.

The Food and Drug Administration last week issued an emergency authorization that will allow the distribution of hydroxychloroquine and similar experimental drugs to the general public from the federal government’s stockpile of medical supplies. Two drug companies, Novartis and Bayer, donated more than 30 million doses to the stockpile, which appears to be what Trump was referring to when he discussed building a stockpile on Sunday.

COVID-19 Symptoms Survey
Help researchers at the Regenstrief Institute track the outbreak
Go to the survey

The Department of Health and Human Services also recently approved hydroxychloroquine and two similar drugs, chloroquine and hydrochloroquine, for “compassionate use,” making them available to extremely ill patients who have exhausted other treatment options.

Local governments such as New York and Michigan have reported promising anecdotal results from the use of hydroxychloroquine to treat the virus. But it has scant scientific backing. The University of Marseilles study most often cited by the drug’s boosters received pushback from other academics in the field, and the journal in which it was published said last week that the study “does not meet the Society’s expected standard.”

Many Trump-friendly pundits, however, are convinced of the drug’s effectiveness, most notably those on Fox News shows from which the president is known to take policy cues.

Read more at The Daily Beast.

South Dakota to Hold First Statewide Clinical Trial of Hydroxychloroquine .
The drug has shown signs that it could be an effective treatment, but without clinical trials officials have been unable to determine its efficacy and safety.On Monday, Noem announced a clinical trial would begin, making South Dakota the first state to hold statewide clinical trials. President Donald Trump championed the drug as a possible treatment for the virus but sufficient clinical trials haven't been conducted to determine its efficacy or the safety of its use.

—   Share news in the SOC. Networks
usr: 11
This is interesting!